Effect of sustained virologic response on liver-related mortality among individuals living with hepatitis C by treatment era: A population-based retrospective cohort study
PLOS One · 06.10.2025 · 20 (10) · e0333584
DOI: 10.1371/journal.pone.0333584 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS One, online erschienen am 06.10.2025. Verfasst von Aysegul Erman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto General Hospital Research Institute, University Health Network, Tor…. Hauptthemen laut MEDLINE: Antiviral Agents, Sustained Virologic Response, Hepatitis C, Hepatitis C, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institute of Health Research, Canada Research Chair in Economics of Infectious Diseases, Ontario Ministry of Health and Long-Term Care.
Abstract (Originalsprache)
Purpose
Sustained virologic response (SVR) is a validated surrogate marker for successful hepatitis C virus (HCV) treatment. Historically, interferon-based therapies, the standard of care for decades, offered only limited efficacy with respect to SVR. The recent introduction of highly effective direct-acting antivirals (DAAs) revolutionised treatment, expanding treatment eligibility among individuals with advanced liver disease (ALD) and drug/alcohol-related substance use disorder. Given these clinical policy shifts, we assessed the real-world impact of SVR on liver-related death for these key clinical groups for whom treatment had previously been less feasible.
Methods
We conducted a population-based, cohort study of Ontario residents with HCV viremia between January 1st, 1999, and December 31st, 2018, with follow-up to May 31st, 2021 (N = 73,411) and used cause-specific hazard models to explore the association between SVR and liver-related death.
Results
SVR was associated with a significant reduction in liver-related deaths (adjusted hazard ratio [aHR]: 0.22, 95%CI: 0.20–0.24). This benefit was consistent across all levels of liver disease severity, including individuals with (aHR: 0.11, 95%CI: 0.06–0.18) and without (aHR: 0.13, 95%CI: 0.10–0.17) cirrhosis, individuals with ALD (aHR: 0.24, 95%CI: 0.22–0.27) as well as among individuals with (aHR: 0.24, 95%CI: 0.21–0.27) and without (aHR: 0.21, 95%CI: 0.18–0.24) substance use disorder.
Conclusions
This study demonstrates the real-world impact of SVR on liver-related mortality and highlights the value of early treatment and continued support for populations who are marginalised.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Toronto Health Economics and Technology Assessment Collaborative (THETA), Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
- ICES, Toronto, ON, Canada.
- School of Pharmacy, University of Waterloo, Kitchener, ON, Canada.
- Division of Infectious Diseases, Jewish General Hospital, McGill University, Montreal, QC, Canada.
- British Columbia Centre for Disease Control (BCDC), Vancouver, BC, Canada.
- Department of Family and Community Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Aysegul Erman, Farinaz Forouzannia, Naveed Janjua, Beate Sander
Förderung
- Canadian Institute of Health Research
- Canada Research Chair in Economics of Infectious Diseases
- Ontario Ministry of Health and Long-Term Care
Zitieren
APA
Erman, A., Everett, K., Wong, W. W. L., Forouzannia, F., Greenaway, C., Janjua, N., Kwong, J. C., & Sander, B. (2025). Effect of sustained virologic response on liver-related mortality among individuals living with hepatitis C by treatment era: A population-based retrospective cohort study. PLOS One, 20(10), e0333584. https://doi.org/10.1371/journal.pone.0333584
Vancouver
Erman A, Everett K, Wong WWL, Forouzannia F, Greenaway C, Janjua N, et al. Effect of sustained virologic response on liver-related mortality among individuals living with hepatitis C by treatment era: A population-based retrospective cohort study. PLOS One. 2025;20(10):e0333584. doi:10.1371/journal.pone.0333584
BibTeX
@article{Erman2025,
author = {Erman, Aysegul and Everett, Karl and Wong, William W L and Forouzannia, Farinaz and Greenaway, Christina and Janjua, Naveed and Kwong, Jeffrey C and Sander, Beate},
title = {Effect of sustained virologic response on liver-related mortality among individuals living with hepatitis C by treatment era: A population-based retrospective cohort study},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0333584},
doi = {10.1371/journal.pone.0333584}
}
EUVIMED